Santarus, (FRA:TW4A) Cash Flow for Dividends : €0.0 Mil (TTM As of Sep. 2013)

View and export this data going back to . Start your Free Trial

What is Santarus, Cash Flow for Dividends?

Santarus,'s cash flow for dividends for the three months ended in Sep. 2013 was €0.0 Mil. Its cash flow for dividends for the trailing twelve months (TTM) ended in Sep. 2013 was €0.0 Mil.

Note: A negative number here means the payment of dividends. When pays more dividends, the absolute value gets bigger.

Santarus, Cash Flow for Dividends Historical Data

The historical data trend for Santarus,'s Cash Flow for Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Santarus, Cash Flow for Dividends Chart

Santarus, Annual Data

Trend

Dec03

Dec04

Dec05

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Cash Flow for Dividends

Get a 7-Day Free Trial

Santarus, Quarterly Data
	Dec08	Mar09	Jun09	Sep09	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13
Cash Flow for Dividends	Get a 7-Day Free Trial															-	-	-	-	-

Santarus, Cash Flow for Dividends Calculation

Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Cash Flow for Dividends for the trailing twelve months (TTM) ended in Sep. 2013 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.0 Mil.

Santarus, Cash Flow for Dividends Related Terms

Thank you for viewing the detailed overview of Santarus,'s Cash Flow for Dividends provided by GuruFocus.com. Please click on the following links to see related term pages.

Santarus, (FRA:TW4A) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Santarus, Inc. (FRA:TW4A) » Definitions » Cash Flow for Dividends

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.santarus.com

Santarus, Inc. was incorporated on December 6, 1996 as a California corporation and did not commence significant business activities until late 1998. On July 9, 2002, the Company reincorporated in the State of Delaware. The Company is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by physician specialists. It sells brand prescription products primarily to pharmaceutical wholesalers, who in turn seek to distribute the products to retail pharmacies, mail order pharmacies, hospitals and other institutional customers. The Company's current commercial efforts are focused on five products: UCERIS, extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis and ZEGERID for the treatment of certain upper gastrointestinal disorders are promoted to gastroenterologists; GLUMETZA and CYCLOSET tablets, which are indicated as adjuncts to diet and exercise to improve glycemic control in adults with type 2 diabetes; and FENOGLIDE tablets, which is indicated as an adjunct to diet to reduce high cholesterol. The pipeline products include the investigational drug RUCONEST for treatment of acute attacks of hereditary angioedema.

Santarus, (FRA:TW4A) Headlines

No Headlines